Hepatotoxicity due to chenodeoxycholic acid supplementation in an infant with cerebrotendinous xanthomatosis: implications for treatment

European Journal of Pediatrics

Volumn 175, Issue 1, 2016, Pages 143-146

  Huidekoper, Hidde H ^a,b   Vaz, Frédéric M ^b   Verrips, Aad ^c   Bosch, Annet M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Cerebrotendinous xanthomatosis; Chenodeoxycholic acid; Hepatotoxicity; Infant; Newborn screening; Treatment

Indexed keywords

ALCOHOL DERIVATIVE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHENODEOXYCHOLIC ACID; CHOLESTANETETROL; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTANOL; GAMMA GLUTAMYLTRANSFERASE; GLUCURONIC ACID; INOSITOL; PENTOL; UNCLASSIFIED DRUG; VITAMIN K GROUP;

APGAR SCORE; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BRAIN INFARCTION; CASE REPORT; CEREBROTENDINOUS XANTHOMATOSIS; CHILD; CONVULSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEEDBACK SYSTEM; FEEDING DIFFICULTY; FEMALE; GENE MUTATION; HEPATOMEGALY; HUMAN; INFANT; JAUNDICE; LETHARGY; LIVER SIZE; METABOLIC REGULATION; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARECHOVIRUS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; PSYCHOMOTOR DEVELOPMENT; SUPPLEMENTATION; TOXIC HEPATITIS; VIRUS ENCEPHALITIS; CHEMICAL AND DRUG INDUCED LIVER INJURY; COMPLICATION; METABOLISM; NEWBORN; NEWBORN SCREENING; PICORNAVIRUS INFECTION; XANTHOMATOSIS, CEREBROTENDINOUS;

CHEMICAL AND DRUG INDUCED LIVER INJURY; CHENODEOXYCHOLIC ACID; CHILD, PRESCHOOL; ENCEPHALITIS, VIRAL; FEMALE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PARECHOVIRUS; PICORNAVIRIDAE INFECTIONS; XANTHOMATOSIS, CEREBROTENDINOUS;

EID: 84954386291     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-015-2584-7     Document Type: Article

References (11)

1. Berginer VM, Gross B, Morad K, Kfir N, Morkos S, Aaref S, Falik-Zaccai TC (2009) Chronic diarrhea and juvenile cataracts: think cerebrotendinous xanthomatosis and treat. Pediatrics 123:143–147. doi:10.1542/peds.2008-0192
2. Clayton PT, Casteels M, Mieli-Vergani G, Lawson AM (1995) Familial giant cell hepatitis with low bile acid concentrations and increased urinary excretion of specific bile alcohols: a new inborn error of bile acid synthesis? Pediatr Res 37:424–431. doi:10.1203/00006450-199504000-00007
3. Clayton PT, Verrips A, Sistermans E, Mann A, Mieli-Vergani G, Wevers R (2002) Mutations in the sterol 27-hydroxylase gene (CYP27A) cause hepatitis of infancy as well as cerebrotendinous xanthomatosis. J Inherit Metab Dis 25:501–513
4. Debarber AE, Luo J, Star-Weinstock M, Purkayastha S, Geraghty MT, Chiang JP, Merkens LS, Pappu AS, Steiner RD (2014) A blood test for cerebrotendinous xanthomatosis with potential for disease detection in newborns. J Lipid Res 55:146–154. doi:10.1194/jlr.P043273
5. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365–1368
6. Pierre G, Setchell K, Blyth J, Preece MA, Chakrapani A, McKiernan P (2008) Prospective treatment of cerebrotendinous xanthomatosis with cholic acid therapy. J Inherit Metab Dis 31(Suppl 2):S241–S245. doi:10.1007/s10545-008-0815-z
7. Salen G, Meriwether TW, Nicolau G (1975) Chenodeoxycholic acid inhibits increased cholesterol and cholestanol synthesis in patients with cerebrotendinous xanthomatosis. Biochem Med 14:57–74
8. Song P, Zhang Y, Klaassen CD (2011) Dose-response of five bile acids on serum and liver bile acid concentrations and hepatotoxicty in mice. Toxicol Sci 123:359–367. doi:10.1093/toxsci/kfr177
9. van Heijst AF, Verrips A, Wevers RA, Cruysberg JR, Renier WO, Tolboom JJ (1998) Treatment and follow-up of children with cerebrotendinous xanthomatosis. Eur J Pediatr 157:313–316
10. Verrips A, Hoefsloot LH, Steenbergen GC, Theelen JP, Wevers RA, Gabreels FJ, van Engelen BG, van den Heuvel LP (2000) Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 123(Pt 5):908–919
11. Yahalom G, Tsabari R, Molshatzki N, Ephraty L, Cohen H, Hassin-Baer S (2013) Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid: early versus late diagnosis. Clin Neuropharmacol 36:78–83. doi:10.1097/WNF.0b013e318288076a